

Form PTO-1449 (modified)

Atty. Docket No.
UTC:504/PARSerial No.
08/726,211

List of Patents and Publications for Applicant's

Applicant

RECEIVED

JUL 10 2002

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
October 4, 1996Group:
1805

TECH CENTER 1600/2900

U.S. Patent Documents
See Page 1-2Foreign Patent Documents
See Page 2Other Art
See Page 2-5

U.S. Patent Documents

Eam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.
AS	A14	4,480,041	10/30/84	Myles <i>et al.</i>	436	508	
	A15	4,721,612	01/26/88	Janoff <i>et al.</i>	424	1.21	
	A16	4,924,624	05/15/90	Suhadolnik <i>et al.</i>	514	44	
	A17	5,030,442	07/09/91	Uster <i>et al.</i>	424	45	
	A18	5,049,388	09/17/91	Knight <i>et al.</i>	424	450	
	A19	5,087,617	02/11/92	Smith	514	44	
	A20	5,098,890	03/24/92	Gewirtz <i>et al.</i>	514	44	
	A21	5,100,662	03/31/92	Bolcsak <i>et al.</i>	424	450	
	A22	5,112,962	05/12/92	Letsinger <i>et al.</i>	536	25.3	
	A23	5,188,897	02/23/93	Suhadolnik <i>et al.</i>	428	402.2	
	A24	5,248,671	09/28/93	Smith	514	44	
	A25	5,264,618	11/23/93	Felgner <i>et al.</i>	560	224	
	A26	5,271,941	12/21/93	Cho-Chung	424	450	
	A27	5,279,957	01/18/94	Gross	435	348	
	A28	5,320,962	06/14/94	Stiles <i>et al.</i>	435	252.3	
	A29	5,324,654	06/28/94	Bredesen	435	376	
	A30	5,560,923	10/01/96	Rahman <i>et al.</i>	424	450	
	A31	5,665,710	09/09/97	Rahman <i>et al.</i>	514	44	
	A32	5,756,122	05/26/98	Thierry <i>et al.</i>	424	450	
	A33	5,817,811	10/06/98	Breipohl <i>et al.</i>	544	264	
	A34	5,855,911	01/05/99	Lopez-Berestein <i>et al.</i>	424	450	
	A35	5,874,553	02/23/99	Peyman <i>et al.</i>	536	22.1	
AS	A36	5,908,635	06/01/99	Thierry	424	450	

Examiner:

ASULL


Date Considered:

11/20/03

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with net communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

BEST AVAILABLE COPY



Form PTO-1449 (modified)Atty. Docket No.
UTC:504/PARSerial No.
08/726,211


List of Patents and Publications for Applicant's

Applicant

Tormo et al.

Filing Date:
October 4, 1996Group:
1805**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

U.S. Patent Documents
See Page 1-2Foreign Patent Documents
See Page 2Other Art
See Page 2-5

TECH CENTER 1600/2900

JUL 10 2002

RECEIVED

Foreign Patent Documents

Eam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
DS	B6	CA 2,171,589	03/12/96	Canada			
Also See parent or relevance	B7	DE 4110085	03/27/91	Germany			No
DS	B8	WO 89/06977	08/10/89	PCT			
	B9	WO 90/09180	08/23/90	PCT			
	B10	WO 90/10488	09/20/90	PCT			
	B11	WO 91/16901	11/14/91	PCT			
	B12	WO 92/21330	12/10/92	PCT			
	B13	WO 93/07883	04/29/93	PCT			
	B14	WO 93/11245	06/10/93	PCT			
	B15	WO 94/04545	03/03/94	PCT			
	B16	WO 94/05259	03/17/94	PCT			
DS	B17	WO 96/40062	12/19/96	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Eam. Init.	Ref. Des.	Citation
DS	C95	Agris et al., "Inhibition of vesicular stomatitis virus protein synthesis and infection by sequence-specific oligodeoxyribonucleosidemethylphosphonates," <i>Biochemistry</i> , 25:6268-6275, 1986.
	C96	Akhtar et al., "Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes)," <i>Nucleic Acids Research</i> , 19(20): 5551-5559, 1991.
DS	C97	Akhtar et al., "Release of antisense oligodeoxynucleotide analogues from liposomes: implications for cellular transport and drug delivery," 128th Meeting of British Pharmaceutical Conference 1991, United Kingdom, September 10-13, 1991, <i>J. Pharm. Pharmacol.</i> , 43 (Suppl.): Abstract 24P, 1991.

Examiner:

Date Considered:

11/20/03

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with net communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

BEST AVAILABLE COPY

Form PTO-1449 (modified)

Atty. Docket No.
UTC:504/PARSerial No.
08/726,211

List of Patents and Publications for Applicant's

Applicant

Tormo et al.

Filing Date:
October 4, 1996Group:
1805

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents
See Page 1-2Foreign Patent Documents
See Page 2Other Art
See Page 2-5

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Eam. Init.	Ref. Des.	Citation
AS	C98	Arad et al., "Use of reconstituted sendai virus envelopes for fusion-mediated microinjection of double-stranded RNA: Inhibition of protein synthesis in interferon-treated cells," <i>Biochimica et Biophysica Acta</i> , 859:88-94, 1986.
	C99	Bennett et al., "Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides," <i>Molecular Pharmacology</i> , 41(6):1023-1033, 1992.
	C100	Boiziau et al., "Modified oligonucleotides in rabbit reticulocytes: uptake, stability and antisense properties," <i>Biochimie</i> , 73:1403-1408, 1991.
	C101	Branch, A., "A good antisense molecule is hard to find," <i>TIBS</i> , 23: 45-49, 1998.
	C102	Budker et al., "Cell membranes as barriers for antisense constructions," <i>Antisense Research and Development</i> , 2:177-184, 1992.
	C103	Capaccioli et al., "Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum," <i>Biochemical and Biophysical Research Communications</i> , 197(2):818-825, 1993.
	C104	Citro et al., "Chemical modification of ligands for cell receptors to introduce foreign compounds into the cells," <i>Colon & Rectum</i> , 37(2):S127-S132, 1994.
	C105	Gerwitz et al., "Facilitating oligonucleotide delivery: helping antisense delivery on its promise," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 93: 3161-3163, 1996.
	C106	Gura, "Antisense has growing pains," <i>Science</i> , 270:575-577, 1995.
	C107	International Search Report from the Patent Cooperation Treaty, March 14, 1997
	C108	Keller et al., "Synthesis and hybridization properties of oligonucleotides containing 2'-O-modified ribonucleotides," <i>Nucleic Acids Research</i> , 21(19):4499-4505, 1993.
	C109	Krieg et al., "Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy," <i>Proc. Natl. Acad. Sci., USA</i> , 90:1048-1052, 1993.
AS	C110	Leonetti et al., "Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication," <i>Proc. Natl. Acad. Sci. USA</i> , 87:2448-2451, 1990.

Examiner:


Date Considered:

11/20/03

EAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with net communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

BEST AVAILABLE COPY



TECH CENTER 1600/2900

JUL 19 2002

RECEIVED

Form PTO-1449 (modified)Atty. Docket No.
UTC:504/PARSerial No.
08/726,211

List of Patents and Publications for Applicant's

Applicant

INFORMATION DISCLOSURE STATEMENT

Tormo et al.

(Use several sheets if necessary)

Filing Date:
October 4, 1996Group:
1805U.S. Patent Documents
See Page 1-2Foreign Patent Documents
See Page 2Other Art
See Page 2-5**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Eam. Init.	Ref. Des.	Citation
	C111	Loke et al., "Characterization of oligonucleotide transport into living cells," <i>Proc. Natl. Acad. Sci. USA</i> , 86:3474-3478, 1989.
	C112	Martiat et al., "Retrovirally transduced antisense sequences stably suppress P210 ^{BCR-ABL} expression and inhibit the proliferation of BCR/ABL-containing cell lines," <i>Blood</i> , 81(2):502-509, 1993.
	C113	Miller et al., "Gene Transfer and antisense nucleic acid techniques," <i>Parasitology Today</i> , 10(3):92-97, 1994.
	C114	Miller, "Oligonucleoside methylphosphonates as antisense reagents," <i>Bio/Technology</i> , 9:358-362, April 1991.
	C115	Moody et al., "Regiospecific inhibition of DNA duplication by antisense phosphate-methylated oligodeoxynucleotides," <i>Nucleic Acids Research</i> , 17(12):4769-4782, 1989. (Abstract)
	C116	Renneisen et al., "Inhibition of expression of human immunodeficiency virus-1 <i>in vitro</i> by antibody-targeted liposomes containing antisense RNA to the <i>env</i> region," <i>The Journal of Biological Chemistry</i> , 265(27):16337-16342, 1990.
	C117	Rojanasakul, "Antisense oligonucleotide therapeutics: drug delivery and targeting," <i>Advanced Drug Delivery Reviews</i> , 18:115-131, 1996.
	C118	Shea et al., "Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates," <i>Nucleic Acids Research</i> , 18(13):3777-3783, 1990.
	C119	Stein et al., "Antisense oligonucleotides as therapeutic agents - is the bullet really magical?," <i>Science</i> , 261:1004-1012, 1993.
	C120	Stein et al., "Oligodeoxynucleotides as inhibitors of gene expression: A review," <i>Cancer Research</i> , 48(10):2635-2944, 1988.
	C121	Stull et al., "Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects, pharmaceutical research," 12(4):465-483, 1995.
	C122	Szczylik et al., "Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides," <i>Science</i> , 253:562-565, 1991.
	C123	Taj et al., "Inhibition of P210 ^{BCR/ABL} expression in K562 cells by electroporation with an Antisense oligonucleotide," <i>Leukemia and Lymphoma</i> , 3:201-208, 1990.
	C124	Thierry et al., "Liposomal delivery as a new approach to transport antisense oligonucleotides," <i>Gene Regulation, Biology of Antisense RNA and DNA</i> , 1: 147-161, 1992.


Eaminer:

Date Considered: 11/20/03

EAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with net communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

BEST AVAILABLE COPY



Form PTO-1449 (modified)

Atty. Docket No.

UTC:504/PAR

Serial No.

08/726,211

RECEIVED

List of Patents and Publications for Applicant's

Applicant

JUL 10 2002

INFORMATION DISCLOSURE STATEMENT

Tormo et al.

TECH CENTER 1600/2900

(Use several sheets if necessary)

Filing Date:

October 4, 1996

Group:

1805

U.S. Patent Documents

See Page 1-2

Foreign Patent Documents

See Page 2

Other Art

See Page 2-5

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Eam. Init.	Ref. Des.	Citation
DS	C125	Tidd et al., "Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence methylphosphonateoligonucleotide analogues," <i>Anti-Cancer Drug Design</i> , 3:117-127, 1988.
	C126	Tidd et al., "Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups," <i>Be. J. Cancer</i> , 60:343-350, 1989.
	C127	Tsuchida et al., "Iron-ligand bonding properties of synthetic iron-porphyrin complexes with oxygen transporting ability in aqueous media," <i>J. Chem. Soc. Dalton Transactions</i> , 10:2455-2458, 1987.
	C128	Uhlmann et al., "Antisense oligonucleotides: a new therapeutic principal," <i>Chemical Reviews</i> , 90(4):543-584, 1990.
	C129	Vasanthakumaret al., "Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates," <i>Cancer Communications</i> , 1(4):225-232, 1989.
	C130	Wagner, "Gene inhibition using antisense oligodeoxynucleotides," <i>Nature</i> , 372:333-335, 1994.
	C131	Weiss, "Upping the antisense ante scientists bet on profits from reverse genetics," <i>Science News</i> , 139:108-109, 1991.
	C132	Wickstrom, "Antisense DNA therapeutics neutral analogs and their stereochemistry," <i>Raven Press Ser. Mol. Cell. Biol.</i> , 1:119-132, 1992.
	C133	Wu-Pong, "Oligonucleotides: Opportunities for drug therapy and research, pharmaceutical technology," 18:102-114, 1984.
DS	C134	Yeoman et al., "Lipofectin enhances cellular uptake of antisense DNA while inhibiting tumor cell growth," <i>Antisense Research and Development</i> , 2:51-59, 1992.

BEST AVAILABLE COPY


Eaminer:

Date Considered:

11/20/03

EAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with net communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)



Form PTO-1449 (modified)	Atty. Docket No. UTXC:504	Serial No. 08/726,211
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Gabriel Lopez-Berestein <i>et al.</i>	
	Filing Date: October 4, 1996	Group: 1636
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1

RECEIVED

AUG 22 2002

TECH CENTER 1600/2900

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
DS	C135	Grever and Chabner, "Cancer Drug Discovery and Developoment," <i>Cancer Principles & Practice of Oncology</i> , 5 th Edition, Lippicott-Raven Publishers, 19:385-394, 1997.
DS	C136	Kaneda <i>et al.</i> , "Increased Expression of DNA cointroduced with nuclear protein in adult rat liver," <i>Science</i> , 242:375-378, 1989.
DS	C137	Kato <i>et al.</i> , "Expression of hepatitis B virus surface antigen in adult rat liver," <i>J. Biol. Chem.</i> , 266:3361-3364, 1991.
DS	C138	Nicolau <i>et al.</i> , "Liposomes as carriers for in vivo gene transfer and expression," <i>Methods in Enzymology</i> , 149:157-176, 1987.
DS	C139	Wong <i>et al.</i> , "Appearance of β -lactamase activity in animal cells upon liposome-mediated gene transfer," <i>Gene</i> , 10:87-94, 1980.
DS	C140	Zon, "Pharmaceutical considerations," <i>Oligodeoxynucleotides</i> , Jack S. Cohen, Ed., CRC Press, 11:233-247, 1989.

25195679.1

EXAMINER:  DATE CONSIDERED: 11/20/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

#44

RECEIVED

FEB 28 2003

TECH CENTER 1600/2900

Form PTO-1449 (modified)

Atty. Docket No.
UTXC:504

Serial No.
08/726,211

Department of Patents and Publications for Applicant's

Applicant
Mar Tormo *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:
October 4, 1996

Group:
1636

(Use several sheets if necessary)

U.S. Patent Documents
See Page 1

Foreign Patent Documents
See Page 1

Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
DS	A36	4,229,360	10/21/80	Schneider <i>et al.</i>	260	403	8/4/78
DS	A37	4,394,448	7/19/83	Szoka, Jr. <i>et al.</i>	435	172	4/24/80
DS	A38	4,469,863	9/4/84	Ts'o <i>et al.</i>	536	27	11/12/80
DS	A39	4,835,263	5/30/89	Nguyen <i>et al.</i>	536	27	12/18/86
DS	A40	4,837,028	6/6/89	Allen	424	450	12/24/86
DS	A41	4,904,582	2/27/90	Tullis	435	6	6/11/87
DS	A42	4,920,016	4/24/90	Allen <i>et al.</i>	424	450	12/18/87
DS	A43	5,094,785	3/10/92	Law <i>et al.</i>	264	4.3	11/22/89
DS	A44	5,279,833	1/18/94	Rose	424	450	4/4/90
DS	A45	5,376,646	12/27/94	Pittrof <i>et al.</i>	514	78	6/16/93
DS	A46	5,378,825	1/3/95	Cook <i>et al.</i>	536	25.34	5/21/91
DS	A47	5,527,538	6/18/96	Baldeschwieler	424	1.21	6/25/93
DS	A48	5,661,018	8/24/97	Ashley <i>et al.</i>	435	172.3	6/6/95
DS	A49	5,696,248	12/9/97	Peyman <i>et al.</i>	536	22.1	6/5/95
DS	A50	5,705,385	1/6/98	Bally <i>et al.</i>	435	320.1	6/7/95
DS	A51	5,750,669	5/12/98	Rosch <i>et al.</i>	536	24.3	8/1/94
DS	A52	5,831,048	11/3/98	Schwichoffer <i>et al.</i>	536	23.1	5/9/94
DS	A53	5,831,066	11/3/98	Reed	536	24.5	6/5/95
DS	A54	5,874,224	2/23/99	Bandman <i>et al.</i>	435	6	3/11/97
DS	A55	5,891,714	4/6/99	Ashley <i>et al.</i>	435	320.1	6/6/95
DS	A56	5,976,567	11/2/99	Wheeler <i>et al.</i>	454	450	6/6/96
DS	A57	6,015,886	1/18/00	Dale <i>et al.</i>	536	23.1	2/5/97
DS	A58	6,034,235	3/7/00	Sugiyama <i>et al.</i>	536	24.5	5/24/96


25263529.1

EXAMINER: *DS*

DATE CONSIDERED: 11/20/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

BEST AVAILABLE COPY



Form PTO-1449 (modified)

Atty. Docket No.

UTXC:504

Serial No.

08/726,211

Office of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 4, 1996

Group:

1636

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
DS	A59	6,040,181	3/21/00	Reed	435	377	5/18/98
DS	A60	6,096,720	8/1/00	Love <i>et al.</i>	514	44	7/24/96
DS	A61	6,110,490	8/29/00	Thierry	424	450	8/4/95
DS	A62	6,120,794	9/19/00	Liu <i>et al.</i>	424	450	9/26/95
DS	A63	6,120,798	9/19/00	Allen <i>et al.</i>	424	450	6/23/98
DS	A64	6,126,965	10/3/00	Kasid <i>et al.</i>	424	450	10/24/97
DS	A65	6,136,965	10/24/00	Bruice <i>et al.</i>	536	25.3	7/2/99
DS	A66	6,211,162 B1	4/3/01	Dale <i>et al.</i>	514	44	3/31/99
DS	A67	6,211,349 B1	4/3/01	Dale <i>et al.</i>	536	23.1	12/30/98
DS	A68	6,277,832 B1	8/21/01	Sugiyama <i>et al.</i>	514	44	1/20/00
DS	A69	6,277,981 B1	8/21/01	Tu <i>et al.</i>	536	25.3	7/2/98
DS	A70	6,291,668 B1	9/18/01	Ziegler <i>et al.</i>	536	24.5	6/5/98
DS	A71	6,326,487 B1	12/4/01	Peyman <i>et al.</i>	536	24.5	7/17/97

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
DS	B18	WO 00/40595	7/13/00	PCT			
DS	B19	WO 02/17852	3/7/02	PCT			
DS	B20	WO 88/04924	7/14/88	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25263529.1

EXAMINER:

DATE CONSIDERED:

11/20/03


EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

RECEIVED

FEB 28 2003

TECH CENTER 1600/2900



BEST AVAILABLE COPY